Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 226

1.
2.

Effectiveness of dabrafenib in the treatment of patients with BRAF V600-mutated metastatic melanoma in a Named Patient Program.

Martin-Algarra S, Hinshelwood R, Mesnage S, Cebon J, Ferrucci PF, Aglietta M, Neyns B, Chiarion-Sileni V, Lindsay CR, Del Vecchio M, Linardou H, Merelli B, Tonini G, Atkinson V, Freivogel K, Stein D, Dalland L, Lau M, Legenne P, Queirolo P, Millward M.

Melanoma Res. 2019 Oct;29(5):527-532. doi: 10.1097/CMR.0000000000000608.

PMID:
31095039
3.

BCL-XL and MCL-1 are the key BCL-2 family proteins in melanoma cell survival.

Lee EF, Harris TJ, Tran S, Evangelista M, Arulananda S, John T, Ramnac C, Hobbs C, Zhu H, Gunasingh G, Segal D, Behren A, Cebon J, Dobrovic A, Mariadason JM, Strasser A, Rohrbeck L, Haass NK, Herold MJ, Fairlie WD.

Cell Death Dis. 2019 Apr 24;10(5):342. doi: 10.1038/s41419-019-1568-3.

4.

Genomic Analysis of Circulating Tumor DNA Using a Melanoma-Specific UltraSEEK Oncogene Panel.

Gray ES, Witkowski T, Pereira M, Calapre L, Herron K, Irwin D, Chapman B, Khattak MA, Raleigh J, Hatzimihalis A, Cebon J, Sandhu S, McArthur GA, Millward M, Ziman M, Dobrovic A, Wong SQ.

J Mol Diagn. 2019 May;21(3):418-426. doi: 10.1016/j.jmoldx.2018.12.001. Epub 2019 Feb 5.

PMID:
30731208
5.

Association of good oncological response to therapy with the development of rheumatic immune-related adverse events following PD-1 inhibitor therapy.

Liew DFL, Leung JLY, Liu B, Cebon J, Frauman AG, Buchanan RRC.

Int J Rheum Dis. 2019 Feb;22(2):297-302. doi: 10.1111/1756-185X.13444. Epub 2018 Nov 22.

PMID:
30549256
6.

Perspective: cancer vaccines in the era of immune checkpoint blockade.

Cebon J.

Mamm Genome. 2018 Dec;29(11-12):703-713. doi: 10.1007/s00335-018-9786-z. Epub 2018 Nov 16. Review.

7.

Rheumatic immune-related adverse events secondary to anti-programmed death-1 antibodies and preliminary analysis on the impact of corticosteroids on anti-tumour response: A case series.

Mitchell EL, Lau PKH, Khoo C, Liew D, Leung J, Liu B, Rischin A, Frauman AG, Kee D, Smith K, Brady B, Rischin D, Gibson A, Mileshkin L, Klein O, Weickhardt A, Arulananda S, Shackleton M, McArthur G, Östör A, Cebon J, Solomon B, Buchanan RR, Wicks IP, Lo S, Hicks RJ, Sandhu S.

Eur J Cancer. 2018 Dec;105:88-102. doi: 10.1016/j.ejca.2018.09.027. Epub 2018 Nov 13.

PMID:
30439628
8.

Real-world efficacy and toxicity of combined nivolumab and ipilimumab in patients with metastatic melanoma.

Parakh S, Randhawa M, Nguyen B, Warburton L, Hussain MA, Cebon J, Millward M, Yip D, Ali S.

Asia Pac J Clin Oncol. 2019 Feb;15(1):26-30. doi: 10.1111/ajco.13100. Epub 2018 Nov 13.

PMID:
30426665
9.

Isolation and characterization of NY-ESO-1-specific T cell receptors restricted on various MHC molecules.

Bethune MT, Li XH, Yu J, McLaughlin J, Cheng D, Mathis C, Moreno BH, Woods K, Knights AJ, Garcia-Diaz A, Wong S, Hu-Lieskovan S, Puig-Saus C, Cebon J, Ribas A, Yang L, Witte ON, Baltimore D.

Proc Natl Acad Sci U S A. 2018 Nov 6;115(45):E10702-E10711. doi: 10.1073/pnas.1810653115. Epub 2018 Oct 22.

10.

Neutrophil to lymphocyte ratio is an independent predictor of outcome for patients undergoing definitive resection for stage IV melanoma.

Kanatsios S, Melanoma Project M, Li Wai Suen CSN, Cebon JS, Gyorki DE.

J Surg Oncol. 2018 Nov;118(6):915-921. doi: 10.1002/jso.25138. Epub 2018 Sep 9.

PMID:
30196539
11.

Oncolytic Virotherapy Promotes Intratumoral T Cell Infiltration and Improves Anti-PD-1 Immunotherapy.

Ribas A, Dummer R, Puzanov I, VanderWalde A, Andtbacka RHI, Michielin O, Olszanski AJ, Malvehy J, Cebon J, Fernandez E, Kirkwood JM, Gajewski TF, Chen L, Gorski KS, Anderson AA, Diede SJ, Lassman ME, Gansert J, Hodi FS, Long GV.

Cell. 2018 Aug 9;174(4):1031-1032. doi: 10.1016/j.cell.2018.07.035. No abstract available.

12.

Multiplex immunohistochemistry accurately defines the immune context of metastatic melanoma.

Halse H, Colebatch AJ, Petrone P, Henderson MA, Mills JK, Snow H, Westwood JA, Sandhu S, Raleigh JM, Behren A, Cebon J, Darcy PK, Kershaw MH, McArthur GA, Gyorki DE, Neeson PJ.

Sci Rep. 2018 Jul 24;8(1):11158. doi: 10.1038/s41598-018-28944-3.

13.

Delayed Autoimmune Toxicity Occurring Several Months After Cessation of Anti-PD-1 Therapy.

Parakh S, Cebon J, Klein O.

Oncologist. 2018 Jul;23(7):849-851. doi: 10.1634/theoncologist.2017-0531. Epub 2018 Apr 17.

14.

Characterising the phenotypic evolution of circulating tumour cells during treatment.

Tsao SC, Wang J, Wang Y, Behren A, Cebon J, Trau M.

Nat Commun. 2018 Apr 16;9(1):1482. doi: 10.1038/s41467-018-03725-8.

15.

Autoantibodies May Predict Immune-Related Toxicity: Results from a Phase I Study of Intralesional Bacillus Calmette-Guérin followed by Ipilimumab in Patients with Advanced Metastatic Melanoma.

Da Gama Duarte J, Parakh S, Andrews MC, Woods K, Pasam A, Tutuka C, Ostrouska S, Blackburn JM, Behren A, Cebon J.

Front Immunol. 2018 Mar 2;9:411. doi: 10.3389/fimmu.2018.00411. eCollection 2018.

16.

Divergent T-cell receptor recognition modes of a HLA-I restricted extended tumour-associated peptide.

Chan KF, Gully BS, Gras S, Beringer DX, Kjer-Nielsen L, Cebon J, McCluskey J, Chen W, Rossjohn J.

Nat Commun. 2018 Mar 12;9(1):1026. doi: 10.1038/s41467-018-03321-w.

17.

Long-Term Outcomes in Patients With BRAF V600-Mutant Metastatic Melanoma Who Received Dabrafenib Combined With Trametinib.

Long GV, Eroglu Z, Infante J, Patel S, Daud A, Johnson DB, Gonzalez R, Kefford R, Hamid O, Schuchter L, Cebon J, Sharfman W, McWilliams R, Sznol M, Redhu S, Gasal E, Mookerjee B, Weber J, Flaherty KT.

J Clin Oncol. 2018 Mar 1;36(7):667-673. doi: 10.1200/JCO.2017.74.1025. Epub 2017 Oct 9.

PMID:
28991513
18.

Patient-reported outcomes in KEYNOTE-006, a randomised study of pembrolizumab versus ipilimumab in patients with advanced melanoma.

Petrella TM, Robert C, Richtig E, Miller WH Jr, Masucci GV, Walpole E, Lebbe C, Steven N, Middleton MR, Hille D, Zhou W, Ibrahim N, Cebon J.

Eur J Cancer. 2017 Nov;86:115-124. doi: 10.1016/j.ejca.2017.08.032. Epub 2017 Oct 4.

19.

Intercellular Resistance to BRAF Inhibition Can Be Mediated by Extracellular Vesicle-Associated PDGFRβ.

Vella LJ, Behren A, Coleman B, Greening DW, Hill AF, Cebon J.

Neoplasia. 2017 Nov;19(11):932-940. doi: 10.1016/j.neo.2017.07.002. Epub 2017 Sep 28.

20.

Pooled Analysis Safety Profile of Nivolumab and Ipilimumab Combination Therapy in Patients With Advanced Melanoma.

Sznol M, Ferrucci PF, Hogg D, Atkins MB, Wolter P, Guidoboni M, Lebbé C, Kirkwood JM, Schachter J, Daniels GA, Hassel J, Cebon J, Gerritsen W, Atkinson V, Thomas L, McCaffrey J, Power D, Walker D, Bhore R, Jiang J, Hodi FS, Wolchok JD.

J Clin Oncol. 2017 Dec 1;35(34):3815-3822. doi: 10.1200/JCO.2016.72.1167. Epub 2017 Sep 15.

PMID:
28915085
21.

Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma.

Wolchok JD, Chiarion-Sileni V, Gonzalez R, Rutkowski P, Grob JJ, Cowey CL, Lao CD, Wagstaff J, Schadendorf D, Ferrucci PF, Smylie M, Dummer R, Hill A, Hogg D, Haanen J, Carlino MS, Bechter O, Maio M, Marquez-Rodas I, Guidoboni M, McArthur G, Lebbé C, Ascierto PA, Long GV, Cebon J, Sosman J, Postow MA, Callahan MK, Walker D, Rollin L, Bhore R, Hodi FS, Larkin J.

N Engl J Med. 2017 Oct 5;377(14):1345-1356. doi: 10.1056/NEJMoa1709684. Epub 2017 Sep 11. Erratum in: N Engl J Med. 2018 Nov 29;379(22):2185.

22.

Oncolytic Virotherapy Promotes Intratumoral T Cell Infiltration and Improves Anti-PD-1 Immunotherapy.

Ribas A, Dummer R, Puzanov I, VanderWalde A, Andtbacka RHI, Michielin O, Olszanski AJ, Malvehy J, Cebon J, Fernandez E, Kirkwood JM, Gajewski TF, Chen L, Gorski KS, Anderson AA, Diede SJ, Lassman ME, Gansert J, Hodi FS, Long GV.

Cell. 2017 Sep 7;170(6):1109-1119.e10. doi: 10.1016/j.cell.2017.08.027. Erratum in: Cell. 2018 Aug 9;174(4):1031-1032.

23.

CMTM6 maintains the expression of PD-L1 and regulates anti-tumour immunity.

Burr ML, Sparbier CE, Chan YC, Williamson JC, Woods K, Beavis PA, Lam EYN, Henderson MA, Bell CC, Stolzenburg S, Gilan O, Bloor S, Noori T, Morgens DW, Bassik MC, Neeson PJ, Behren A, Darcy PK, Dawson SJ, Voskoboinik I, Trapani JA, Cebon J, Lehner PJ, Dawson MA.

Nature. 2017 Sep 7;549(7670):101-105. doi: 10.1038/nature23643. Epub 2017 Aug 16.

24.

Standard-dose pembrolizumab in combination with reduced-dose ipilimumab for patients with advanced melanoma (KEYNOTE-029): an open-label, phase 1b trial.

Long GV, Atkinson V, Cebon JS, Jameson MB, Fitzharris BM, McNeil CM, Hill AG, Ribas A, Atkins MB, Thompson JA, Hwu WJ, Hodi FS, Menzies AM, Guminski AD, Kefford R, Kong BY, Tamjid B, Srivastava A, Lomax AJ, Islam M, Shu X, Ebbinghaus S, Ibrahim N, Carlino MS.

Lancet Oncol. 2017 Sep;18(9):1202-1210. doi: 10.1016/S1470-2045(17)30428-X. Epub 2017 Jul 17.

PMID:
28729151
25.

PLX8394, a new generation BRAF inhibitor, selectively inhibits BRAF in colonic adenocarcinoma cells and prevents paradoxical MAPK pathway activation.

Tutuka CSA, Andrews MC, Mariadason JM, Ioannidis P, Hudson C, Cebon J, Behren A.

Mol Cancer. 2017 Jun 28;16(1):112. doi: 10.1186/s12943-017-0684-x.

26.

Phase II Study of First-Line Trebananib Plus Sorafenib in Patients with Advanced Hepatocellular Carcinoma.

Abou-Alfa GK, Blanc JF, Miles S, Ganten T, Trojan J, Cebon J, Liem AK, Lipton L, Gupta C, Wu B, Bass M, Hollywood E, Ma J, Bradley M, Litten J, Saltz LB.

Oncologist. 2017 Jul;22(7):780-e65. doi: 10.1634/theoncologist.2017-0058. Epub 2017 Jun 7.

27.

Efficacy of anti-PD-1 therapy in patients with melanoma brain metastases.

Parakh S, Park JJ, Mendis S, Rai R, Xu W, Lo S, Drummond M, Rowe C, Wong A, McArthur G, Haydon A, Andrews MC, Cebon J, Guminski A, Kefford RF, Long GV, Menzies AM, Klein O, Carlino MS.

Br J Cancer. 2017 Jun 6;116(12):1558-1563. doi: 10.1038/bjc.2017.142. Epub 2017 May 18.

28.

Whole-genome landscapes of major melanoma subtypes.

Hayward NK, Wilmott JS, Waddell N, Johansson PA, Field MA, Nones K, Patch AM, Kakavand H, Alexandrov LB, Burke H, Jakrot V, Kazakoff S, Holmes O, Leonard C, Sabarinathan R, Mularoni L, Wood S, Xu Q, Waddell N, Tembe V, Pupo GM, De Paoli-Iseppi R, Vilain RE, Shang P, Lau LMS, Dagg RA, Schramm SJ, Pritchard A, Dutton-Regester K, Newell F, Fitzgerald A, Shang CA, Grimmond SM, Pickett HA, Yang JY, Stretch JR, Behren A, Kefford RF, Hersey P, Long GV, Cebon J, Shackleton M, Spillane AJ, Saw RPM, López-Bigas N, Pearson JV, Thompson JF, Scolyer RA, Mann GJ.

Nature. 2017 May 11;545(7653):175-180. doi: 10.1038/nature22071. Epub 2017 May 3.

PMID:
28467829
29.

Reply to 'Comment on 'Efficacy and toxicity of treatment with the anti-CTLA-4 antibody ipilimumab in patients with metastatic melanoma after prior anti-PD-1 therapy''.

Bowyer S, Prithviraj P, Lorigan P, Larkin J, McArthur G, Atkinson V, Millward M, Khou M, Diem S, Ramanujam S, Kong B, Liniker E, Guminski A, Parente P, Andrews MC, Parakh S, Cebon J, Long GV, Carlino MS, Klein O.

Br J Cancer. 2017 Apr 11;116(8):e15. doi: 10.1038/bjc.2017.59. Epub 2017 Mar 21. No abstract available.

30.

A pilot study of peripheral blood BDCA-1 (CD1c) positive dendritic cells pulsed with NY-ESO-1 ISCOMATRIX™ adjuvant.

Davis ID, Quirk J, Morris L, Seddon L, Tai TY, Whitty G, Cavicchiolo T, Ebert L, Jackson H, Browning J, MacGregor D, Wittke F, Winkels G, Alex R, Miloradovic L, Maraskovsky E, Chen W, Cebon J.

Immunotherapy. 2017 Mar;9(3):249-259. doi: 10.2217/imt-2016-0132. Epub 2017 Feb 10.

PMID:
28183192
31.

Advance care planning in patients with incurable cancer: study protocol for a randomised controlled trial.

Johnson S, Clayton J, Butow PN, Silvester W, Detering K, Hall J, Kiely BE, Cebon J, Clarke S, Bell ML, Stockler M, Beale P, Tattersall MH.

BMJ Open. 2016 Dec 1;6(12):e012387. doi: 10.1136/bmjopen-2016-012387.

32.

Optimizing combination dabrafenib and trametinib therapy in BRAF mutation-positive advanced melanoma patients: Guidelines from Australian melanoma medical oncologists.

Atkinson V, Long GV, Menzies AM, McArthur G, Carlino MS, Millward M, Roberts-Thomson R, Brady B, Kefford R, Haydon A, Cebon J.

Asia Pac J Clin Oncol. 2016 Dec;12 Suppl 7:5-12. doi: 10.1111/ajco.12656.

PMID:
27905182
33.

Systems analysis identifies miR-29b regulation of invasiveness in melanoma.

Andrews MC, Cursons J, Hurley DG, Anaka M, Cebon JS, Behren A, Crampin EJ.

Mol Cancer. 2016 Nov 16;15(1):72.

34.

Restoring p53 Function in Human Melanoma Cells by Inhibiting MDM2 and Cyclin B1/CDK1-Phosphorylated Nuclear iASPP.

Lu M, Breyssens H, Salter V, Zhong S, Hu Y, Baer C, Ratnayaka I, Sullivan A, Brown NR, Endicott J, Knapp S, Kessler BM, Middleton MR, Siebold C, Jones EY, Sviderskaya EV, Cebon J, John T, Caballero OL, Goding CR, Lu X.

Cancer Cell. 2016 Nov 14;30(5):822-823. doi: 10.1016/j.ccell.2016.09.019. No abstract available.

35.

Iterative sorting reveals CD133+ and CD133- melanoma cells as phenotypically distinct populations.

Grasso C, Anaka M, Hofmann O, Sompallae R, Broadley K, Hide W, Berridge MV, Cebon J, Behren A, McConnell MJ.

BMC Cancer. 2016 Sep 9;16(1):726. doi: 10.1186/s12885-016-2759-2.

36.

Sentinel node biopsy for melanoma: The medical oncology perspective.

Menzies AM, Atkinson VG, Brown MP, Carlino MS, Cebon J, Guminski A, Kefford RF, Long GV, McArthur G, McNeil CM, Millward M, Sandhu S.

Aust Fam Physician. 2015 Dec;44(12):875-6. No abstract available.

PMID:
27505912
37.

Identifying and targeting determinants of melanoma cellular invasion.

Jayachandran A, Prithviraj P, Lo PH, Walkiewicz M, Anaka M, Woods BL, Tan B, Behren A, Cebon J, McKeown SJ.

Oncotarget. 2016 Jul 5;7(27):41186-41202. doi: 10.18632/oncotarget.9227.

38.

Efficacy and toxicity of treatment with the anti-CTLA-4 antibody ipilimumab in patients with metastatic melanoma after prior anti-PD-1 therapy.

Bowyer S, Prithviraj P, Lorigan P, Larkin J, McArthur G, Atkinson V, Millward M, Khou M, Diem S, Ramanujam S, Kong B, Liniker E, Guminski A, Parente P, Andrews MC, Parakh S, Cebon J, Long GV, Carlino MS, Klein O.

Br J Cancer. 2016 May 10;114(10):1084-9. doi: 10.1038/bjc.2016.107. Epub 2016 Apr 28.

39.

Altered Expression and Splicing of ESRP1 in Malignant Melanoma Correlates with Epithelial-Mesenchymal Status and Tumor-Associated Immune Cytolytic Activity.

Yao J, Caballero OL, Huang Y, Lin C, Rimoldi D, Behren A, Cebon JS, Hung MC, Weinstein JN, Strausberg RL, Zhao Q.

Cancer Immunol Res. 2016 Jun;4(6):552-61. doi: 10.1158/2326-6066.CIR-15-0255. Epub 2016 Apr 4.

40.

Transketolase-like 1 ectopic expression is associated with DNA hypomethylation and induces the Warburg effect in melanoma cells.

Jayachandran A, Lo PH, Chueh AC, Prithviraj P, Molania R, Davalos-Salas M, Anaka M, Walkiewicz M, Cebon J, Behren A.

BMC Cancer. 2016 Feb 22;16:134. doi: 10.1186/s12885-016-2185-5.

41.

Mismatch in epitope specificities between IFNγ inflamed and uninflamed conditions leads to escape from T lymphocyte killing in melanoma.

Woods K, Knights AJ, Anaka M, Schittenhelm RB, Purcell AW, Behren A, Cebon J.

J Immunother Cancer. 2016 Feb 16;4:10. doi: 10.1186/s40425-016-0111-7. eCollection 2016.

42.

Capture and On-chip analysis of Melanoma Cells Using Tunable Surface Shear forces.

Tsao SC, Vaidyanathan R, Dey S, Carrascosa LG, Christophi C, Cebon J, Shiddiky MJ, Behren A, Trau M.

Sci Rep. 2016 Jan 27;6:19709. doi: 10.1038/srep19709.

43.

Overall Survival and Durable Responses in Patients With BRAF V600-Mutant Metastatic Melanoma Receiving Dabrafenib Combined With Trametinib.

Long GV, Weber JS, Infante JR, Kim KB, Daud A, Gonzalez R, Sosman JA, Hamid O, Schuchter L, Cebon J, Kefford RF, Lawrence D, Kudchadkar R, Burris HA 3rd, Falchook GS, Algazi A, Lewis K, Puzanov I, Ibrahim N, Sun P, Cunningham E, Kline AS, Del Buono H, McDowell DO, Patel K, Flaherty KT.

J Clin Oncol. 2016 Mar 10;34(8):871-8. doi: 10.1200/JCO.2015.62.9345. Epub 2016 Jan 25. Erratum in: J Clin Oncol. 2019 Feb 1;37(4):355.

PMID:
26811525
44.

Clinicopathological characteristics associated with BRAF(K601E) and BRAF(L597) mutations in melanoma.

Voskoboynik M, Mar V, Mailer S, Colebatch A, Fennessy A, Logan A, Hewitt C, Cebon J, Kelly J, McArthur G.

Pigment Cell Melanoma Res. 2016 Mar;29(2):222-8. doi: 10.1111/pcmr.12450. Epub 2016 Jan 17.

PMID:
26643848
45.

Tumour procurement, DNA extraction, coverage analysis and optimisation of mutation-detection algorithms for human melanoma genomes.

Wilmott JS, Field MA, Johansson PA, Kakavand H, Shang P, De Paoli-Iseppi R, Vilain RE, Pupo GM, Tembe V, Jakrot V, Shang CA, Cebon J, Shackleton M, Fitzgerald A, Thompson JF, Hayward NK, Mann GJ, Scolyer RA.

Pathology. 2015 Dec;47(7):683-93. doi: 10.1097/PAT.0000000000000324. Erratum in: Pathology. 2016 Jan;48(1):104.

PMID:
26517638
46.

Mycoplasma Infection Alters Cancer Stem Cell Properties in Vitro.

Gedye C, Cardwell T, Dimopoulos N, Tan BS, Jackson H, Svobodová S, Anaka M, Behren A, Maher C, Hofmann O, Hide W, Caballero O, Davis ID, Cebon J.

Stem Cell Rev Rep. 2016 Feb;12(1):156-61. doi: 10.1007/s12015-015-9630-8.

PMID:
26514153
47.

First-in-Man Dose-Escalation Study of the Selective BRAF Inhibitor RG7256 in Patients with BRAF V600-Mutated Advanced Solid Tumors.

Dienstmann R, Lassen U, Cebon J, Desai J, Brown MP, Evers S, Su F, Zhang W, Boisserie F, Lestini B, Schostack K, Meresse V, Tabernero J.

Target Oncol. 2016 Apr;11(2):149-56. doi: 10.1007/s11523-015-0381-x.

PMID:
26310975
48.

Cellular Mechanisms Underlying Complete Hematological Response of Chronic Myeloid Leukemia to BRAF and MEK1/2 Inhibition in a Patient with Concomitant Metastatic Melanoma.

Andrews MC, Turner N, Boyd J, Roberts AW, Grigg AP, Behren A, Cebon J.

Clin Cancer Res. 2015 Dec 1;21(23):5222-34. doi: 10.1158/1078-0432.CCR-15-0393. Epub 2015 Jul 22.

49.

Monitoring response to therapy in melanoma by quantifying circulating tumour DNA with droplet digital PCR for BRAF and NRAS mutations.

Tsao SC, Weiss J, Hudson C, Christophi C, Cebon J, Behren A, Dobrovic A.

Sci Rep. 2015 Jun 22;5:11198. doi: 10.1038/srep11198.

50.

Phosphoproteomic Analysis of Cell-Based Resistance to BRAF Inhibitor Therapy in Melanoma.

Parker R, Vella LJ, Xavier D, Amirkhani A, Parker J, Cebon J, Molloy MP.

Front Oncol. 2015 May 15;5:95. doi: 10.3389/fonc.2015.00095. eCollection 2015.

Supplemental Content

Support Center